| Literature DB >> 28194107 |
Ean-Jeong Seo1, Ching-Fen Wu1, Zulfiqar Ali2, Yan-Hong Wang2, Shabana I Khan3, Larry A Walker3, Ikhlas A Khan3, Thomas Efferth1.
Abstract
Green tea consumption is associated with chemoprevention of many cancer types. Fresh tea leaves are rich in polyphenolic catechins, which can constitute up to 30% of the dry leaf weight. While the polyphenols of green tea have been well investigated, it is still largely unknown, whether or not non-phenolic constituents also reveal chemopreventive and anti-metastatic effects. In this study, we investigated the effects of a fraction of green tea rich in phenolic compounds (PF), a non-phenolic fraction (NPF), which contains glyceroglycolipids (GGL), and a pure glyceroglycolipid compound isolated from the non-phenolic fraction in human cancer. Dried green tea leaves were extracted and applied to a Sephadex LH-20 column. The resazurin reduction assay was used to investigate the cytotoxicity of green tea samples toward human HepG2 hepatocellular carcinoma and normal AML12 hepatocytes cells. Gene expression profiling was performed by mRNA microarray hybridization and the microarray results were validated by RT-PCR. The scratch migration assay was used to investigate the effects of green tea samples on cell migration in vitro. The changes of microtubule dynamics were observed using fluorescence microscopy. PF and NPF were prepared from methanol extract of green tea. A GGL was isolated from NPF. All three green tea samples did not show significant cytotoxic activity up to 10 μg/mL in both HepG2 and AML12 cells, whereas cytotoxicity of the control drug doxorubicin was observed with both cell lines (IC50 on AML12: 0.024 μg/mL, IC50 on HepG2: 2.103 μg/mL). We identified three sets of genes differentially expressed upon treatment with the green tea samples. The genes were associated with cytoskeleton formation, cellular movement, and morphology. The correlation coefficients between mRNA expression values determined by microarray and RT-PCR were R = 0.94. HepG2 and U2OS cells treated with green tea extracts showed the delayed closures. Besides, the number of distinct tubulin filaments decreased upon treatment with green tea samples. We identified not only PF, but also glyceroglycolipids in NPF as contributing factors to the chemopreventive effects of green tea. Both PF and NPF of green tea inhibited cancer cell migration by the disassembly of microtubules, even though they were not cytotoxic.Entities:
Keywords: chemoprevention; green tea; microarray; nutrigenomics; theaceae
Year: 2016 PMID: 28194107 PMCID: PMC5278262 DOI: 10.3389/fphar.2016.00398
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Primer nucleotide sequences used for real-time RT-PCR experiments.
| Fw: 5′- ATTCTGAACTGTCAGTGCTTGC -3′ | |
| Rev: 5′- CTTCTTAGGTTCTGGGTAACCG -3′ | |
| Fw: 5′- GTTTGGCGTTGGCAGTCAGGTAAT -3′ | |
| Rev: 5′- CACAGCACGACTCTGCAAGTGTAT -3′ | |
| Fw: 5′- AAC AGG CCG AAT TCT CTG AT -3′ | |
| Rev: 5′- CCA TTC CGA AGA ACT TCC AT -3′ | |
| Fw: 5′- TGA CTG TGG TGC CGT ACT TG -3′ | |
| Rev: 5′- CAC CGT GAA GTC CTG AGT GT -3′ | |
| Fw: 5′- GGTTGAAGTTGACATCTGACGA -3′ | |
| Rev: 5′- CTTGTGCAACACATGTGAAT -3′ |
Figure 1UPLC-UV analysis of (A) phenolic fraction and (B) catechins standards (cross reference with Table .
Figure 2Chromatogram of non-phenolic fraction (cross reference with Table .
Contents (% = mg/100 mg sample) of catechins and caffeine in phenolic fraction.
| 1 | (–)-Gallocatechin | 1.83 |
| 2 | Caffeine | 2.71 |
| 3 | Epigallocatechin | 14.5 |
| 4 | Catechin | 0.40 |
| 5 | (–)-Epicatechin | 2.23 |
| 6 | Epigallocatechin gallate | 46.9 |
| 7 | Gallocatehin gallate | 0.81 |
| 8 | Epicatechin gallate | 8.55 |
| 9 | (–)-Catechin gallate | 0.10 |
Contents of six glyceroglycolipid standards in non-phenolic fraction NPF.
| G1 | Gingerglycolipid A | 0.172 |
| G2 | (2 | 0.021 |
| G3 | (2 | 0.11 |
| G4 | (2 | 0.436 |
| G5 | (2 | 0.645 |
| G6 | (2 | 0.105 |
Figure 3Cytotoxicity of green tea samples (A) doxorubicin, (B) PF, (C) NPF, (D) GGL, (E) PF+NPF, (F) PF+GGL, (G) NPF+GGL, and (H) PF+NPF+GGL toward HepG2 hepatocellular carcinoma cells and AML12 normal hepatocytes. Significantly different between cell viability of doxorubicin and cell viability of tested samples according to Student's t-test, *0.01 < P ≤ 0.05, **P ≤ 0.01, blue for AML12 and red for HepG2 cells.
Figure 4Identified molecular functions of (A) phenolic fraction, (B) non-phenolic fraction, and (C) glyceroglycolipid of green tea by Ingenuity pathway analyses.
Top up- and down-regulated genes in HepG2 cells upon treatment of green tea samples (GGL, PF, or NPF) for 24 h.
| Top up-regulated genes | 11.3 | 13.2 | 158.7 | |||
| 10.0 | 8.6 | 72.0 | ||||
| 8.9 | 8.5 | 65.8 | ||||
| 7.8 | 8.3 | 64.9 | ||||
| 7.7 | 7.6 | 57.7 | ||||
| 6.7 | 7.3 | 56.9 | ||||
| 5.7 | 7.1 | 56.9 | ||||
| 5.5 | 6.6 | 55.7 | ||||
| 5.5 | 6.0 | 53.4 | ||||
| 5.3 | 5.5 | 52.0 | ||||
| Top down-regulated genes | −29.0 | −17.4 | −1951.0 | |||
| −18.3 | −8.7 | −1562.9 | ||||
| −15.3 | −8.4 | −1530.7 | ||||
| −14.5 | −7.5 | −1184.4 | ||||
| −13.9 | −7.0 | −989.1 | ||||
| −13.3 | −6.2 | −982.3 | ||||
| −13.3 | −5.4 | −897.6 | ||||
| −13.1 | −5.2 | −861.1 | ||||
| −11.2 | −5.0 | −765.4 | ||||
| SEC61G | −10.9 | AKT3 | −4.6 | RPS15 | −760.1 | |
FC: fold change.
Fold changes of mRNA expression were detected by microarray hybridizations.
Cell migration-associated genes deregulated in HepG2 cells after treatment with GGL.
| Cellular movement | Heparin-binding EGF-like growth factor | −4.7 | NC | NC | |
| Transforming growth factor, β-receptor 1 | NC | 2.5 | NC | ||
| Transforming growth factor, β-receptor 2 (70/80 kDa) | −6.7 | −2.8 | NC | ||
| Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | −3.2 | NC | NC | ||
| Mitogen-activated protein kinase kinase kinase 7 | −4.5 | NC | NC | ||
| pim-1 oncogene | −4.9 | NC | NC | ||
| Regulator of G-protein signaling 4 | 3.8 | 2.9 | NC | ||
| v-myc myelocytomatosis viral oncogene homolog (avian) | −8.3 | −3.0 | NC | ||
| pim-1 oncogene | −4.9 | NC | NC | ||
| Profilin 1 | −5.8 | −2.8 | NC | ||
| Cadherin 11, type 2, OB-cadherin (osteoblast) | NC | −2.5 | NC | ||
| Chondroitin sulfate proteoglycan 4 | NC | −2.7 | NC | ||
| Polycystic kidney disease 1 (autosomal dominant) | NC | −3.5 | NC | ||
| v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, γ) | NC | −4.6 | NC | ||
| Bone morphogenetic protein receptor, type II (serine/threonine kinase) | NC | 2.5 | NC | ||
| Protein kinase C, 1 | NC | −2.4 | NC | ||
| Protein tyrosine phosphatase type IVA, member 2 | NC | −2.8 | NC | ||
| ADAM metallopeptidase domain 15 | NC | 3.2 | NC | ||
| Myosin, heavy chain 10, non-muscle | NC | 3.1 | NC | ||
| Serine/threonine kinase 11 | −29.0 | NC | −308.7 | ||
| NME/NM23 nucleoside diphosphate kinase 1 | NC | NC | −333.1 | ||
| Y box binding protein 1 | NC | NC | −84.4 | ||
| ADP-ribosylation factor-like 3 | NC | NC | 56.886 | ||
| Aurora kinase A | NC | NC | −70.5 | ||
| Beclin 1, autophagy related | NC | NC | −84.4 | ||
| Citron (rho-interacting, serine/threonine kinase 21) | NC | NC | −72.0 | ||
| Nucleolar and spindle associated protein 1 | NC | NC | −58.5 | ||
| Ras homolog family member A | NC | NC | −82.1 | ||
| Transmembrane 4 L six family member 1 | NC | NC | −69.1 | ||
| Tetratricopeptide repeat domain 19 | NC | NC | −78.8 | ||
| Forkhead box P1 | NC | NC | −124.5 | ||
| DEK oncogene | NC | NC | −40.8 | ||
| Growth differentiation factor 15 | NC | NC | −57.7 | ||
| Chemokine (C-C motif) ligand 20 | NC | NC | −116.2 | ||
| Complement component 1, q subcomponent binding protein | NC | NC | −45.3 | ||
| Placental growth factor | NC | NC | −259.6 | ||
| BCL2-associated athanogene | NC | NC | −90.5 | ||
| Cytoskeleton formation | ADP-ribosylation factor 6 | −3.4 | NC | NC | |
| Rho guanine nucleotide exchange factor (GEF) 10 | 3.4 | NC | NC | ||
| Rho guanine nucleotide exchange factor (GEF) 3 | −2.9 | NC | NC | ||
| Guanine nucleotide binding protein (G protein), β-polypeptide 1 | −4.0 | NC | NC | ||
| Gelsolin | −14.5 | NC | NC | ||
| NCK adaptor protein 1 | −2.9 | NC | NC | ||
| Protein tyrosine phosphatase, non-receptor type 11 | −3.7 | NC | NC | ||
| Transforming growth factor, beta receptor 2 (70/80kDa) | −6.7 | NC | NC | ||
| Mitogen-activated protein kinase kinase kinase 7 | −4.5 | NC | NC | ||
| Morphology | Golgi phosphoprotein 3 (coat-protein) | −11.2 | −2.8 | NC | |
| High mobility group AT-hook 1 | −2.9 | NC | NC | ||
| Leucine zipper-EF-hand containing transmembrane protein 1 | 2.9 | 2.5 | NC | ||
| Peroxiredoxin 3 | −3.1 | NC | NC | ||
| SEC23 interacting protein | −5.4 | NC | NC | ||
| Metallothionein 1F | −6.2 | −3.1 | NC | ||
| Kruppel-like factor 2 (lung) | −3.8 | NC | NC | ||
| Phosphoinositide kinase, FYVE finger containing | −3.8 | −2.6 | NC | ||
| Leucine zipper, putative tumor suppressor 2 | −4.8 | NC | NC | ||
| Bone marrow stromal cell antigen 2 | −5.8 | NC | −286.0 | ||
| Basic helix-loop-helix family, member e40 | −3.1 | NC | NC | ||
| Transmembrane protein 123 | −9.1 | NC | NC | ||
| c-abl oncogene 1, non-receptor tyrosine kinase | −2.9 | NC | NC | ||
| E1A binding protein p300 | −3.2 | NC | NC | ||
| Cathepsin Z | NC | −3.9 | NC | ||
| Peroxiredoxin 1 | NC | −2.8 | NC | ||
| G protein-coupled receptor 18 | NC | 5.2 | NC | ||
| G protein-coupled receptor 182 | NC | 5.1 | NC | ||
| Matrix metallopeptidase 10 (stromelysin 2) | NC | −2.4 | NC | ||
| Rho guanine nucleotide exchange factor (GEF) 10 | 3.4 | NC | NC | ||
| Rho guanine nucleotide exchange factor (GEF) 3 | −2.9 | NC | NC | ||
| Guanine nucleotide binding protein (G protein), β-polypeptide 1 | −4.0 | NC | NC | ||
| Gelsolin | −14.5 | NC | NC | ||
| NCK adaptor protein 1 | −2.9 | NC | NC | ||
| Protein tyrosine phosphatase, non-receptor type 11 | −3.7 | NC | NC | ||
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, | NC | NC | −132.5 | ||
| Transforming growth factor, β-receptor 2 (70/80kDa) | −6.7 | NC | NC | ||
| Mitogen-activated protein kinase kinase kinase 7 | −4.5 | NC | NC | ||
| Pim-1 oncogene | −4.9 | NC | NC | ||
| Karyopherin α 2 (RAG cohort 1, importin α 1) | NC | NC | −39.9 | ||
| Nucleophosmin (nucleolar phosphoprotein B23, numatrin) | NC | NC | −56.1 | ||
| Cortactin | NC | NC | −126.2 | ||
| CSE1 chromosome segregation 1-like (yeast) | NC | NC | −109.1 | ||
| Reticulon 4 | NC | NC | −132.5 | ||
| Lectin, galactoside-binding, soluble, 3 | NC | NC | −186.1 | ||
| Thymidylate synthetase | NC | NC | −181.0 | ||
NC: no change.
Validation of microarray-based mRNA expression by quantitative real-time RT-PCR (RT-PCR were performed twice).
| HepG2 | Microarray hybridization | GGL | 9.99 | PF | 13.18 | |
| Real-time RT-PCR | 5.19 | 9.57 | ||||
| HepG2 | Microarray hybridization | GGL | 6.68 | PF | 8.28 | |
| Real-time RT-PCR | 1.49 | 1.53 | ||||
| HepG2 | Microarray hybridization | GGL | 5.69 | PF | 7.06 | |
| Real-time RT-PCR | 2.18 | 2.56 | ||||
| HepG2 | Microarray hybridization | GGL | −29.04 | NPF | −308.69 | |
| Real-time RT-PCR | −1.00 | −16.32 |
R-value: 0.94 (Pearson correlation test).
Figure 5Inhibition of migration of HepG2 cells by green tea samples. HepG2 cells were treated with (A) DMSO for 0 h, (B) DMSO for 72 h, (C) phenolic fraction for 0 h, (D) phenolic fraction for 72 h, (E) non-phenolic fraction for 0 h, (F) non-phenolic fraction for 72 h, (G) glyceroglycolipid for 0 h, (H) glyceroglycolipid for 72 h, (I) Quantification of closure of the scratch by TScratch software. Significantly different according to Student's t-test, *P ≤ 0.05.
Figure 6Inhibition of migration of U2OS-GFP-α-tubulin cells by green tea samples. U2OS-GFP-α-tubulin cells were treated with (A) DMSO for 0 h, (B) DMSO for 72 h, (C) phenolic fraction for 0 h, (D) phenolic fraction for 72 h, (E) non-phenolic fraction for 0 h, (F) non-phenolic fraction for 72 h, (G) glyceroglycolipid for 0 h, (H) glyceroglycolipid for 72 h, (I) Quantification of closure of the scratch by TScratch software. Significantly different according to Student's t-test, *P ≤ 0.05.
Figure 7Live cell imaging of U2OS-GFP-α-tubulin cells stably transfected with a GFP fusion construct of α-tubulin cells and treated with (A) DMSO or 25 μg/mL of green tea samples [(B) PF, (C) NPF, or (D) GGL], combinations of (E) PF+NPF (each 12.5 μg/mL), (F) PF+GGL (each 12.5 μg/mL), (G) NPF+GGL (each 12.5 μg/mL), and (H) PF+NPF+GGL (each 8.3 μg/mL).